Erdosteine is a
thiol derivative developed for the treatment of chronic obstructive
bronchitis, including acute infective exacerbation of
chronic bronchitis.
Erdosteine contains 2 blocked sulfhydryl groups which are released following first-pass metabolism. The 3 active metabolites exhibit
mucolytic and
free radical scavenging activity.
Erdosteine modulates mucus production and viscosity and increases mucociliary transport, thereby improving expectoration. It also exhibits inhibitory activity against the effects of
free radicals produced by cigarette
smoke. Clinical studies in patients with
chronic obstructive lung disease have demonstrated the efficacy and tolerability of
erdosteine.
Erdosteine 300mg twice daily reduced
cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than
ambroxol 30mg twice daily. Co-administration of
erdosteine and
amoxicillin in patients with acute infective exacerbation of
chronic bronchitis resulted in higher concentrations of the
antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo.
Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.